Table 2.

Univariate Analysis Between Different Characteristics and iPFS or OS

Variable	iPFS		OS
	HR (95% CI)	P value	HR (95% CI)	P value
Group
CRT + Anlotinib vs CRT	0.58 (0.32–1.03)	0.06	1.08 (0.63–1.87)	0.77
Gender
Female vs Male	1.37 (0.81–2.32)	0.24	1.65 (0.96–2.84)	0.07
Age
≥ 57 years vs < 57 years	1.03 (1–1.06)	0.05	1.04 (1.01–1.08)	0.01
KPS score
90–100 vs 70–80	0.53 (0.31–0.91)	0.02	0.52 (0.30–0.90)	0.02
Smoking history
Yes vs No	1.63 (0.92–2.89)	0.1	1.54 (0.87–2.71)	0.14
Pathological type
Squamous vs adenocarcinoma	0.56 (0.29–1.1)	0.09	0.47 (0.24–0.90)	0.02
T stage
Tx	1		–
T1	0.66 (0.22–2)	0.47	0.50 (0.14–1.71)	0.27
T2	0.79 (0.38–1.66)	0.53	1.01 (0.48–2.10)	0.99
T3	0.68 (0.3–1.53)	0.35	0.76 (0.33–1.72)	0.51
T4	0.54 (0.27–1.1)	0.1	0.65 (0.31–1.34)	0.24
N stage
Nx	1		–
N0	0.27 (0.05–1.36)	0.11	0.31 (0.07–1.37)	0.12
N1	0.88 (0.26–2.92)	0.83	0.69 (0.24–2.01)	0.5
N2	0.9 (0.26–3.16)	0.87	0.96 (0.32–2.9)	0.94
N3	0.86 (0.24–3.11)	0.82	0.74 (0.23–2.36)	0.66
Primary site
Left vs right	1.28 (0.75–2.17)	0.36	0.74 (0.43–1.27)	0.27
Number of brain metastases
>3 vs ≤3	1.22 (0.58–2.57)	0.61	1.83 (0.78–4.27)	0.16
Extracranial distant metastasis
Yes vs No	1.14 (0.64–2.02)	0.66	1.1 (0.62–1.96)	0.75
Treatment-line
Zero-Line	1		1
First-Line	0.93 (0.26–3.33)	0.91	0.76 (0.24–2.37)	0.63
Second-Line	1.78 (0.49–6.46)	0.38	0.91 (0.28–2.97)	0.88
Third-Line	1.32 (0.4–4.37)	0.65	0.91 (0.32–2.64)	0.87
Fourth-Line	0.48 (0.1–2.38)	0.37	0.61 (0.15–2.43)	0.48

Abbreviations: OS, overall survival; iPFS, intracranial progression free survival; CRT, cranial radiotherapy; KPS, Karnofsky Performance Status; HR, hazard ratio; CI, confidence interval.